[Summary] A high-tech enterprise specializing in new drug research and developme
Nanjing Cavendish Biotechnology Engineering Co., Ltd. is a high-tech enterprise specializing in new drug research and development. The company was established in November 2006 with a registered capital of RMB 80 million. The company is committed to the research and development of innovative new drug technologies, MAH production, and academic promotion services for developed drugs. Key development areas include anti-tumor drugs (hematological diseases), diabetes drugs, cardiovascular drugs, and anti-infective drugs. All new drugs initiated for research and development are breakthrough therapeutic products in their original treatment fields, striving to add new treatment options to fill gaps in domestic disease treatment areas.
Main business:
The company is primarily engaged in the research and development of innovative new drug technologies. Its main business includes new drug technology transfer, patented technology licensing, holding new drug production approvals (MAH) for contracted manufacturing and sales, academic promotion services for developed drugs, and also accepting collaborative development and contracted development of new drug projects from external parties.
Research and Innovation
In 2010, the company invested in the construction of the F5 R&D office building in Jiangsu Life Science and Technology Innovation Park, Xianlin University Town, Nanjing, equipped with comprehensive and advanced R&D equipment and facilities, with total R&D equipment assets exceeding RMB 50 million. The company has excellent and experienced technical talent support in the field of new drug research, possessing an experienced team for scientific research and industrial implementation. It currently has a research team of nearly 100 professionals in medicinal chemistry, pharmaceutics, pharmaceutical analysis, chemical engineering technology, biological fermentation, and other professional fields. Investment in new drug R&D has increased year by year, exceeding RMB 100 million in 2018.
R&D Achievements:
From 2009 to 2016, the company initiated more than 50 research projects. Around these projects, 42 Chinese invention patent applications were filed, with 22 patents authorized; 8 international invention patent applications were submitted through the PCT route, designated to enter Europe, the United States, Japan, South Korea, Australia, and other countries respectively, with 25 patents authorized.
Representative successfully developed products:
Lenalidomide used for the treatment of multiple myeloma and myelodysplastic syndromes. Our lenalidomide project has currently been approved for marketing. Multiple patented inventions of this project have obtained patent authorization protection in China as well as in the United States and Europe. Listed in China as the first generic drug under patent challenge, our developed lenalidomide has a legitimate basic foundation for patent intellectual property rights, advancing the market launch time of this product in China by nearly 7 years.
In 2023, the company obtained the drug registration approval for "Eplerenone Tablets" among the earlier batches nationwide. This drug is an excellent variety marketed in China, filling the gap in domestic second-generation MRA drugs. The successful development and marketing of blockbuster products marks the company's development entering a new stage, laying a solid foundation with core competitiveness for embracing the era of innovation-driven development in the pharmaceutical industry.
Honors Received:
The company has been recognized as a "High-tech Enterprise," "Jiangsu Province Specialized, Refined, Distinctive and Innovative SME," "Jiangsu Province Technology-based SME," "Nanjing Engineering Technology Center," "Jiangsu Province Patent Implementation Plan Promotion Unit," "Nanjing Qixia District Intellectual Property Advanced Unit," and "Nanjing Qixia District Science and Technology Innovation Advanced Collective."
The company currently offers the following job positions. Outstanding talents who meet the requirements and are interested in joining our team are welcome to contact our Human Resources Department. We welcome your calls! Looking forward to your joining!
What does Nanjing Cavendish Biotechnology Engineering Co., Ltd. require? Who is Cavendish Biotech hiring? Cavendish Biotech recruitment: 工厂生产类占比最多占60.3%,其次是医疗卫生/美容保健类占34.5%. What education can get in at Cavendish Biotech? 大专占比最多占43.1%,其次是硕士占27.6%. High education required at Cavendish Biotech? 硕士占27.6%. Work experience required at Cavendish Biotech? 不限占比最多占36.2%,其次是5-10年占27.6%. Where are the job locations at Cavendish Biotech? 南京占比最多占48.3%,其次是泰州占46.6%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows